Chronic Subdural Hematoma Clinical Trial
Official title:
Middle Meningeal Artery Embolization With Liquid Embolic Agent for Treatment of Chronic Subdural Hematoma
The study evaluates the clinical and imaging outcome of middle meningeal artery (MMA) embolization with liquid embolic agent for treatment of chronic subdural hematoma (CSDH)
This study is a prospective one arm trial designed to assess the safety and efficacy of MMA embolization with liquid embolic agents (onyx/squid/Phil) as the main treatment of CSDH. The subjects are enrolled in the study according to inclusion and exclusion criteria. Imaging and clinical presentations of patients are recorded. Within 48 hours of embolization, patients are assessed with clinical examination and with a brain CT scan to evaluate in any change in their symptoms and CSDH volume. 2-4 weeks after embolization, patients are evaluated in clinic for any change in their symptoms and signs. 60 days after embolization patients are examined clinically and are assessed for SDH volume change in CT scan and MRI. If there is any significant increase in CSDH volume or any deterioration of patient, evacuation of hematoma is considered. MMA embolization is performed under general anesthesia using biplane or monoplane angiography. Femoral or radial accesses are used. Guiding catheter is advanced into external carotid artery in corresponding side. The corresponding MMA is catheterized distally by micro-catheter and is embolized by liquid embolic agents. Patients are discharge next day if they are stable. ;
Status | Clinical Trial | Phase | |
---|---|---|---|
Not yet recruiting |
NCT06347796 -
Chronic Subdural Hematoma Treatment With Embolization Versus Surgery Study
|
N/A | |
Recruiting |
NCT04065113 -
Middle Meningeal Artery Embolization for Chronic Subdural Hematoma
|
N/A | |
Recruiting |
NCT02938468 -
Mgt of Chronic Subdural Hematoma Using Dexamethasone
|
Phase 2/Phase 3 | |
Completed |
NCT03307395 -
Middle Meningeal Artery Embolization for Treatment of Chronic Subdural Hematoma
|
N/A | |
Terminated |
NCT04502745 -
A Study to Evaluate Endoscope-assisted, Minimally-invasive Cortical Access System for Chronic Subdural Evacuation
|
N/A | |
Terminated |
NCT03353259 -
Tocilizumab (RoActemra) and Tranexamic Acid (Cyklokapron) Used as Adjuncts to Chronic Subdural Hematoma Surgery
|
Phase 2/Phase 3 | |
Recruiting |
NCT02568124 -
Tranexamic Acid in Chronic Subdural Hematomas
|
Phase 2/Phase 3 | |
Completed |
NCT02282228 -
Detecting Chronic Subdural Hematoma With Microwave Technology
|
N/A | |
Recruiting |
NCT05143216 -
High Concentration Oxygen Therapy for Pneumocephalus in Chronic Subdural Haematoma: A Prospective Observational Study
|
||
Active, not recruiting |
NCT04816591 -
Middle Meningeal Artery Embolization for the Treatment of Subdural Hematomas With TRUFILL® n-BCA
|
N/A | |
Recruiting |
NCT06401772 -
The Effectiveness and Safety of Body Posture in Preventing Postoperative Recurrence for Chronic Subdural Hematoma
|
N/A | |
Completed |
NCT06134206 -
Burr Hole Ultrasound Study
|
N/A | |
Recruiting |
NCT03666949 -
General Anesthesia Versus Locoregional Anesthesia for Evacuation of Chronic Subdural Hematoma
|
N/A | |
Recruiting |
NCT03280212 -
Tranexamic Acid in the Treatment of Residual Chronic Subdural Hematoma
|
Phase 3 | |
Completed |
NCT03447327 -
Outcome of Single Burr Hole Under Local Anaesthesia in the Management of Chronic Subdural Hematoma
|
N/A | |
Recruiting |
NCT05374681 -
Efficacy of a Minimally Invasive Therapy Adjuvant to the Standards of Care by Cyanoacrylate Embolization
|
N/A | |
Recruiting |
NCT05267184 -
Swedish Trial on Embolization of Middle Meningeal Artery Versus Surgical Evacuation in Chronic Subdural Hematoma
|
N/A | |
Not yet recruiting |
NCT05900557 -
Neurologic Deficits and Recovery in Chronic Subdural Hematoma
|
N/A | |
Completed |
NCT02757235 -
The Swedish Study of Irrigation Fluid Temperature in the Evacuation of Chronic Subdural Hematoma
|
N/A | |
Terminated |
NCT02111785 -
Dexamethasone Versus Burr Hole Craniostomy for Symptomatic Chronic Subdural Hematoma
|
Phase 2/Phase 3 |